No Increase Seen in OD Deaths Involving Buprenorphine During COVID-19
Proportion of overdose deaths did not increase in association with actions taken to ease access to buprenorphine
Proportion of overdose deaths did not increase in association with actions taken to ease access to buprenorphine
OPNT003 is an intranasal formulation containing the high affinity opioid antagonist, nalmefene.
Canadian provinces permitting edible cannabis sales experienced much larger increases in hospitalizations for unintentional poisoning
The table provided is a review of notable updates that occurred in December 2022 for investigational products in development.
RiVive is an opioid antagonist that reverses the effects of opioids, including respiratory depression, sedation, and hypotension.
If approved, the OTC nasal spray would deliver 4mg of naloxone per spray.
For men aged 65 to 74 and 75 years or older, drug overdose death rates were higher for non-Hispanic Black men
Findings even stronger for young people with a recent opioid prescription
If the overdose antidote drug naloxone becomes easier to obtain, it could save lives and help combat the U.S. opioid crisis
Xylazine is centrally-acting alpha2-adrengeric agonist that was originally approved in 1972 as a sedative and analgesic for use in veterinary medicine.